The supplementary information includes:
Supplementary Figure Supplementary Figure -7 . Inhibition of xenograft tumour cell proliferation after the combinatorial treatment using chimera and 5-FU. Table S1 . Efficacy of in vitro survivin knockdown with or without 5-FU treatment in HT-29 tumour-formation as determined in a limiting dilution assay.
Supplementary Figure 1. Aptamer-siRNA chimera structure
The aptamer-siRNA chimera was designed by linking the EpCAM aptamer with a survivinspecific siRNA sequence ( Figure S1a ). For in vivo applications, a 20-kDa PEG was linked to the chimera to increase circulatory half-life. The chimera structure features an asymmetric structure to facilitate recognition by an endogenous Dicer enzyme to cleave the chimera which results in the release of the expected 21-mer siRNA sequence [251] ( Figure S1b ). As control, we used an alternative from of the chimera similar to the original but with 2 point mutations introduced in the siRNA sequence as shown in Figure S1a . These modifications abolished the survivin silencing efficacy but retained the aptamer-binding property, therefore controlling potential immune response-associated gene suppression and EpCAM-binding side-effects. To measure tumour self-renewal, HT-29 cells were treated with 20 nM of the chimera or negative control chimera for 48 hours prior to plating on a 96-well or 6-well ultra-low attachment round bottom plates with or without 2 µM 5-FU at densities of 20, 10, and 5 cells per well. Figure S3 shows representative light microscopy images of tumourspheres in response to various treatments after 5 days of incubation at 37 °C. Figure S2 . Representative images of in vitro tumoursphere assay. A tumoursphere-forming assay in 96-well plates was used to evaluate the potential of a cell to behave as a stem cell, in which a cell sphere with a well-defined border and a diameter larger than 50 µm was considered to be a tumourpshere. Images shown are at 100 x magnification.
Supplementary Figure 3. Targeting survivin enhances oxaliplatin efficacy against HT-29 colorectal cancer stem cells
HT-29 cells were treated with the chimera for 48 hours before trypsinization to prepare single cell suspension. The cells were plated into a round-bottom 96-well ultra-low attachment plates (Corning) with or without 50 nM oxaliplatin at densities of 1, 5, and 20 cells/well. As shown in Figure S2 , there were no significant changes in self-renewal compared to saline control when the cells were treated with either survivin silencing or oxaliplatin. However, oxaliplatin treatment after survivin silencing resulted in approximately 2.7-fold decrease in self-renewal compared to saline control or oxaliplatin mono-treatment. Tumour-bearing NOD/SCID mice underwent intravenous treatments with 2 nmol/mouse of chimera or negative control chimera on days 1, 3, and 5 with or without 30 mg/kg of 5-FU on days 3, 5, and 7. Forty-eight hours after final treatment, tumours were extracted for size comparison ( Figure S4a ) and weighed individually ( Figure S4b) . After in vivo treatment of tumour-bearing mice, the extracted tumours were dissociated into single-cell suspension with collagenase, and the dissociated cells were plated into 96-well low-attachment round bottom plates at various cell densities. After 5 days of incubation at 37 °C, each tumoursphere was examined with light microscopy. Figure S5 shows representative images of each tumoursphere. To measure the efficacy of survivin knockdown with the chimera in combination with 5-FU treatment in the induction of tumour cell apoptosis in vivo, tumours from in vivo-treated NOD/SCIFD mice were paraffin embedded and formalin fixed. The tumour sections were then prepared for TUNEL assay. As shown in Figure S4 , combinatorial treatment of survivin knockdown using the chimera and 5-FU resulted in 200% more apoptosis compared with 5-FU treatment with or without the negative control chimera. 
